literature

HIV mutation literature information.

[Establishment of pharmacological evaluation system for non-nucleoside reverse-transcriptase inhibitors resistant HIV-1].

PMID: 19545051 2009 Yao xue xue bao

Abstract: All nine recombinant VSVG/HIV-mut pseudovirions (VSVG/HIV-wt, VSVG/HIV(-K103N), VSVG/HIV(-Y181C), VSVG/HIV(-L100I,K103N), VSVG/HIV(-Y188L), VSVG/HIV(-K103N,Y181C), VSVG/HIV(-K103N,P225H), VSVG/HIV(-K103N,Y188L), VSVG/HIV(-K103N,G109A) and VSVG/HIV(-K103N,V108I)) had high efficient infectivity.

Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania.

PMID: 19583845 2009 BMC infectious diseases

Table: V108I

Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria.

PMID: 19644383 2009 Journal of acquired immune deficiency syndromes (1999)

Result: The most common NNRTI mutations included: Y181C (168, 49.7%), K103N (123, 36.4%), G190A (89, 26.3%), A98G (66, 19.5%), K101E (59, 17.5%), V108I (52, 15.4%), and V90I (41, 12.1%).

Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors.

PMID: 19734799 2009 Journal of acquired immune deficiency syndromes (1999)

Result: Ten of the 12 samples had a total of 14 non-etravirine resistance mutations including V108I (n=6), P225H (n=3), K101N (n=1), Y188C (n=1).

Result: The accessory NNRTI-resistance mutations P225H (n=3), V108I (n=1), A98G (n=1), and H221Y (n=1) were detected in six of the samples.

Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa.

PMID: 19911963 2009 Clinical infectious diseases

Table: V108I

Molecular characterization of human immunodeficiency virus type 1 (HIV-1) and HIV-2 in Yaounde, Cameroon: evidence of major drug resistance mutations in newly diagnosed patients infected with subtypes other than subtype B.

PMID: 17855574 2008 Journal of clinical microbiology

Abstract: Single mutations associated with resistance to nucleoside reverse transcriptase inhibitors (T215Y/F [n = 3]) and nonnucleoside reverse transcriptase inhibitors (V108I [n = 1], L100I [n = 1], and Y181C [n = 2]) were observed in 7 of 75 (9.3%) group M samples.

Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase.

PMID: 18313784 2008 Virus research

Abstract: V108I (via perturbation of Tyr188 and Tyr181) and K103N (apo-enzyme stabilisation).

Impact of residues in the nonnucleoside reverse transcriptase inhibitor binding pocket on HIV-1 reverse transcriptase heterodimer stability.

PMID: 18336260 2008 Current HIV research

Abstract: We found that the mutations K101A, P225H, Y318F and Y318W decreased RT heterodimer stability whereas K103N, V108I, V108W, Y181C, Y188L, G190A, G190E, G190W and P225W increased RT heterodimer stability.

Transmission networks of drug resistance acquired in primary/early stage HIV infection.

PMID: 19005274 2008 AIDS (London, England)

Result: K103N, V108I, G190A, associated with resistance to NNRTIs.

Binding modes of two novel non-nucleoside reverse transcriptase inhibitors, YM-215389 and YM-228855, to HIV type-1 reverse transcriptase.

PMID: 19024630 2008 Antiviral chemistry & chemotherapy

Abstract: A single amino acid substitution confers only moderate resistance to YM-215389; indeed, four amino acid substitutions (V106L, V108I, E138K and L214F) were necessary for high-level resistance.

Browser Board

Co-occurred Entities

Filtrator